Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
See detailEfficacité et équité dans les systèmes éducatifs : les deux faces d'une même pièce ?
Demeuse, Marc ULg; Crahay, Marcel ULg; Monseur, Christian ULg

in Demeuse, Marc; Baye, Ariane; Straeten, Marie-Hélène (Eds.) Vers une école juste et efficace : 26 contributions sur les systèmes d'enseignement et de formation : une approche internationale (2005)

Detailed reference viewed: 108 (5 ULg)
See detailEfficacité et équité du système éducatif en Communauté française. Les résultats de PISA 2000 et 2003
Baye, Ariane ULg

Conference given outside the academic context (2005)

Detailed reference viewed: 22 (0 ULg)
See detailEfficacité et progrès technique dans l'industrie manufacturière belge
Fecher-Bourgeois, Fabienne ULg; Perelman, Sergio ULg

in Tulkens, Henry (Ed.) Efficacité et Management (1989)

Detailed reference viewed: 23 (3 ULg)
Peer Reviewed
See detailL'"efficacité paradoxale" de la médiation esthétique
Servais, Christine ULg

Conference (2013, October 17)

Il s’agit ici de montrer que le concept de médiation a une portée critique, qu’il s’agit d’un concept propre à séparer, à distinguer, à révéler des enjeux politiques, qu’il n’est pas seulement propre à ... [more ▼]

Il s’agit ici de montrer que le concept de médiation a une portée critique, qu’il s’agit d’un concept propre à séparer, à distinguer, à révéler des enjeux politiques, qu’il n’est pas seulement propre à décrire des pratiques, mais également à les interroger. Le concept de médiation a une portée critique dès lors qu’il questionne le rapport entre communication et politique, notamment à travers la question des normes communes, du “sens commun”, de la transmission, du rôle du conflit, etc. En partant de l’approche de Lamizet, qui conçoit la médiation comme ce qui prend en charge et opère une relation singulier/collectif, je propose d’envisager non pas ce qui s’interpose (dispositifs, médiateurs) entre l’oeuvre et le public, mais bien la relation que le public établit avec l’oeuvre et les dispositifs, en considérant que ceux-ci font médiation, c’est-à-dire inscrivent l’individu dans une forme de communauté. A travers cette conception d’une “médiation esthétique”, on peut réintroduire la notion de médiation culturelle telle qu’elle est comprise par la plupart des auteurs (comme “transformation”, Davallon, 2003, comme “recherche infinie de significations”, Darras, 2003) dans sa dimension non seulement critique mais également politique. Cette approche de la médiation suppose qu’on la décrive en des termes qui permettent de la mettre en relation tant avec l’émancipation (Rancière, 2000, 2008) qu’avec l’aliénation ou la contrainte. Nous verrons alors qu’il faut la décrire comme mésentente (Rancière, 1995), malentendu (Derrida 1990) ou désynchronisation (Stiegler, 2003), c’est-à-dire : “incalculable” (Derrida), asymétrique, et fondée sur la possibilité de l’échec, ce que Rancière appelle l’ “efficacité paradoxale” des oeuvres. [less ▲]

Detailed reference viewed: 20 (0 ULg)
See detailEfficacité productive et rendements d'échelle dans les banques belges
Gathon, Henry-Jean ULg; Grosjean, Fabienne

in Cahiers Economiques de Bruxelles (1991), 130(Summer), 145-160

Detailed reference viewed: 4 (2 ULg)
Full Text
See detailEfficacité, efficience, qualité : quelle évaluation pour quelle Justice ?
Ficet, Joël ULg

Conference (2009, September 18)

Detailed reference viewed: 51 (4 ULg)
Full Text
Peer Reviewed
See detailEFFICACITES TECHNICO-ECONOMIQUES DES SYSTEMES DE PRODUCTION AGRICOLE DANS LE CONTEXTE ACTUEL DES TRANSFORMATIONS AGRAIRES D’UNE COMMUNE DU DELTA DU FLEUVE ROUGE: LE CAS DE LA COMMUNE DE CAM HOANG, DISTRICT DE CAM GIANG, PROVINCE DE HAI HUONG
Phan Dang, Thang ULg; Vu Dinh Ton; Marc Dufumier

in Recueil des résultats des recherches du programme de coopération interuniversitaires (2008)

Ongoing the research on the agricultural and rural dynamics at Cam Hoang commune of the Hai Duong province, situated in the heart of the Red River Delta, for a better understanding the evolution of ... [more ▼]

Ongoing the research on the agricultural and rural dynamics at Cam Hoang commune of the Hai Duong province, situated in the heart of the Red River Delta, for a better understanding the evolution of agricultural systems, we have continually been realized an economic analyze. This study aims to identify and to analyze the economic-technical efficiencies of the five main polyculture-livestock farming systems at different scales, known as farming systems (SP), in the light of the agricultural developmental evolutions in the region. Only 10% of the farm households produce sufficiently for selling an important part of their agricultural production, around 76.5% of the farm households must have an extra-agricultural activity, and only 14.6% rely exclusively to their agricultural activity. One active labor’s revenue varies from 8,365 kd (thousand Vietnam dongs) in the system SP5 to 36,597 kd per year for the farmers of the group SP3b, or one important disparity from 1 to 4.4 times between the households at the same commune. This research enabled to underline a significant number of problems related to the rural development, the durability in agricultural production, but also reveals the positive dynamics within the agricultural households. [less ▲]

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailEfficacy and cardiovascular safety of daclizumab, mycophenolate mofetil,tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter,prospective, pilot trial
Abramowicz, Daniel; Vanrenterghem, Yves; Squifflet, Jean-Paul ULg et al

in Clinical Transplantation (2005), 19

This single-arm, open-label, pilot study was designed to assess the efficacy and cardiovascular safety profile of daclizumab, a humanized monoclonal interleukin (IL)-2Ra antibody, in combination with ... [more ▼]

This single-arm, open-label, pilot study was designed to assess the efficacy and cardiovascular safety profile of daclizumab, a humanized monoclonal interleukin (IL)-2Ra antibody, in combination with mycophenolate mofetil (MMF), tacrolimus, and early corticosteroid withdrawal in renal transplant recipients. Seventy-nine renal allograft recipients were treated with daclizumab (1 mg/kg; five doses starting on the day before transplant and then every two weeks), MMF (1 g b.i.d.), tacrolimus (0.2 mg/kg/d), and low-dose prednisolone, which was withdrawn at day 150 after transplant. The rate of acute rejection was determined at 12 months. Lipid profile, oral glucose tolerance, and adverse events were monitored. Of the 76 patients eligible for analysis, eight (10.5%) developed biopsyproven acute rejection (BPAR). Ten (13.2%) experienced clinical and/or BPAR. Corticosteroids were withdrawn completely in 91% of patients at 12 months. Graft and patient survival were 97.5% and 98.7% respectively. Mean total cholesterol and triglycerides were significantly lower at 12 months post-transplant than at baseline (201 ± 47.5 vs. 190.8 ± 43.6 mg/dL, p ¼ 0.005 and 196.2 ± 133.2 vs. 144.5 ± 76.8 mg/ dL, p < 0.001, respectively). Mean hemoglobin A1c levels did not differ between baseline (5.54%) and 12 months (5.48%). New-onset posttransplant diabetes mellitus occurred in 6.6% of the non-diabetic transplanted patients. The proportion of patients with abnormal oral glucose tolerance test (OGTT) was 47% at 3 months and 39% at 12 months (p ¼ NS). Daclizumab induction in combination with MMF, tacrolimus, and low-dose (followed by withdrawal) prednisolone appears to be effective and safe in patients receiving renal allografts. The regimen appears to be associated with a favorable cardiovascular profile. [less ▲]

Detailed reference viewed: 26 (3 ULg)
Full Text
Peer Reviewed
See detailEfficacy and morbidity of a novel induction treatment for locally advanced NSCLC
Bosquee, Léon ULg; Rinken, Françoise ULg; Bustin, F. et al

in Lung Cancer (2005, July), 49(Suppl. 2), 78

Detailed reference viewed: 22 (6 ULg)
Full Text
Peer Reviewed
See detailEfficacy and Morbidity of a Novel Induction Treatment in Locally Advanced Non Small Cell Lung Cancer (NSCLC)
Barthelemy, Nicole ULg; Rinken, F.; Dekoster, Guy ULg et al

in International Journal of Radiation, Oncology, Biology, Physics (2006), 66(3), 476-477

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF.
Allez, Matthieu; Vermeire, Severine; Mozziconacci, Nicolas et al

in Alimentary Pharmacology & Therapeutics (2009)

Adalimumab (ADA) and certolizumab pegol (CZP) have demonstrated efficacy in Crohn's disease (CD) patients previously treated with infliximab (IFX). Aim: To assess the efficacy and tolerability of a third ... [more ▼]

Adalimumab (ADA) and certolizumab pegol (CZP) have demonstrated efficacy in Crohn's disease (CD) patients previously treated with infliximab (IFX). Aim: To assess the efficacy and tolerability of a third anti-TNF in CD after failure of and/or intolerance to two different anti-TNF. Methods: CD patients who received ADA or CZP after loss of response and/or intolerance to two anti-TNF were included in this retrospective study. Data were collected using a standardized questionnaire. Clinical response, duration, safety and reasons for discontinuation were assessed. Results: Sixty-seven patients treated with CZP (n=40) or ADA (n=27) were included. A clinical response was observed in 41 (61%) at week 6 and 34 patients (51%) at week 20. The probability of remaining under treatment at 3 months, 6 months and 9 months was 68%, 60% and 45%, respectively. At the end of follow-up, the third anti-TNF had been stopped in 36 patients for intolerance (n=13), or failure (n=23). Two deaths were observed. Conclusion: Treatment, with a third anti-TNF (CZP or ADA) agent, of CD patients who have experienced loss of response and/or intolerance to two anti-TNF antibodies, has favorable short- and long-term efficacy and is an option to be considered in patients with no other therapeutic options. [less ▲]

Detailed reference viewed: 36 (5 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
van de Putte, B. A.; Atkins, C.; Malaise, Michel ULg et al

in Annals of the Rheumatic Diseases (2004), 63(5), 508-516

Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed. Methods: In a 26 week, double blind, placebo controlled ... [more ▼]

Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed. Methods: In a 26 week, double blind, placebo controlled, phase III trial, 544 patients with RA were randomised to monotherapy with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, 40 mg weekly, or placebo. The primary efficacy end point was greater than or equal to 20% improvement in the ACR core criteria (ACR20 response). Secondary efficacy end points included ACR50, ACR70, EULAR responses, and the Disability Index of the Health Assessment Questionnaire (HAQ DI). Results: After 26 weeks, patients treated with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, and 40 mg weekly had significantly better response rates than those treated with placebo: ACR20 (35.8%, 39.3%, 46.0%, 53.4%, respectively v 19.1%; pless than or equal to 0.01); ACR50 (18.9%, 20.5%, 22.1%, 35.0% v 8.2%; pless than or equal to 0.05); ACR70 (8.5%, 9.8%, 12.4%, 18.4% v 1.8%; pless than or equal to 0.05). Moderate EULAR response rates were significantly greater with adalimumab than with placebo (41.5%, 48.2%, 55.8%, 63.1% v 26.4%; pless than or equal to 0.05). Patients treated with adalimumab achieved better improvements in mean HAQ DI than those receiving placebo (-0.29, -0.39, -0.38, -0.49 v -0.07; pless than or equal to 0.01). No significant differences were found between adalimumab and placebo treated patients for serious adverse events, serious infections, or malignancies. Injection site reaction occurred in 10.6% and 0.9% of adalimumab and placebo treated patients, respectively (pless than or equal to 0.05). Conclusion: Among patients with RA for whom previous DMARD treatment had failed, adalimumab monotherapy achieved significant, rapid, and sustained improvements in disease activity and improved physical function and was safe and well tolerated. [less ▲]

Detailed reference viewed: 13 (0 ULg)
Peer Reviewed
See detailEfficacy and safety of avocado soybean unsaponifiable (ASU)at two different daily doses in treatment of symptomatic osteoarthritis of the knee (KOA)
Appelboom, T; Reginster, Jean-Yves ULg; Schuermans, J et al

in Osteoarthritis and Cartilage (1999), 7(SA), 117

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy and Safety of Drugs for Paget's Disease of Bone
Reginster, Jean-Yves ULg; Lecart, M. P.

in BONE (1995), 17(5 Suppl), 485-488

Paget's disease of bone is characterized by an anarchic bone turnover starting with excessive resorption caused by structural and functional abnormalities involving osteoclasts. Calcitonin and ... [more ▼]

Paget's disease of bone is characterized by an anarchic bone turnover starting with excessive resorption caused by structural and functional abnormalities involving osteoclasts. Calcitonin and bisphosphonates are now considered as the main therapeutic approaches for this disease. Daily parenteral administration of calcitonin to patients with Paget's disease of bone results in a significant fall in serum alkaline phosphatase and urinary hydroxyproline levels. This treatment has also been reported to be effective in relieving clinical symptoms of the disease, mainly bone pain. The drawbacks of injectable calcitonin have stimulated interest in alternative routes of delivery. Substantial evidence of calcitonin bioavailability and bioefficacy equivalent to those of parenteral administration is currently available for only two alternative routes: nasal spray and rectal suppository. Since many results have been published showing a dramatic effect of several bisphosphonates in Paget's disease of bone, nasal and rectal calcitonin are no longer considered as the treatments of choice in this condition. A major advantage of the use of bisphosphonates over calcitonin in Paget's disease is that biochemical and histologic suppression of disease activity may persist for many years after the cessation of treatment. Oral etidronate and intravenous pamidronate have been extensively used and have provided satisfactory benefits to the patient. Since the risk/benefit ratio of alendronate does not appear to be completely positive, it is likely that the future of treatment of Paget's disease of bone will be based on the oral formulation of the new bisphosphonates, including tiludronate, risedronate or dimethyl-pamidronate. [less ▲]

Detailed reference viewed: 6 (2 ULg)